BACKGROUND: Experimental animal research shows that treatment with @entity889 improves recovery after focal @entity1779 . If the effect were similar in @entity1 , @entity4944 treatment could have a major impact on recovery from @entity64 . OBJECTIVES: The objective of this review was to assess the effects of @entity4944 treatment in @entity1 with @entity64 . SEARCH STRATEGY: We searched the Cochrane @entity64 Group Trials Register (last searched November 2002). In addition, we searched the Cochrane Controlled Trials Register (Cochrane Library, Issue 4 2002), MEDLINE (1966-September 2002), EMBASE (1980-November 2002), and Science Citation Index (1992-December 2002). The reference lists of all relevant articles and reviews were checked, and we contacted researchers in the field to identify further published and unpublished studies. SELECTION CRITERIA: Randomized unconfounded trials comparing @entity4944 with placebo. DATA COLLECTION AND ANALYSIS: Two reviewers independently selected trials for inclusion, assessed trial quality and extracted the data. MAIN RESULTS: Seven studies involving 172 @entity1 were included. The quality of the trials varied but was generally high. Based on two trials (85 @entity1 ) there was no evidence that @entity4944 treatment reduced @entity204 or dependence (Peto's odds ratio, [Peto OR] 1.54; 95% Confidence Interval [CI] 0.64 to 3.73). In these two trials, there were imbalances at baseline, with more serious strokes allocated to @entity4944 . This imbalance may account for the trend for more @entity204 at the end of follow-up among @entity4944 allocated @entity1 (Peto OR 3.33; 95% CI 0.99 to 11.24). Based on 4 studies (95 @entity1 ) there was evidence of a better relative change in motor function according to the Fugl-Meyer motor scale (Weighted Mean Difference, [WMD] -8.17 points; 95% CI -13.58 to -2.76) and based on 1 study (21 @entity1 ) there was evidence of a better change in language function as assessed by the Porch Index of Communicative Ability score (WMD -7.51 points; 95% CI -14.42 to -0.60) in @entity4944 allocated @entity1 . REVIEWER'S CONCLUSIONS: At present, too few @entity1 have been studied to draw any definite conclusions about the effects of @entity4944 treatment on recovery from @entity64 . The suggested benefits on motor and language function, and the non-significant trend towards increased risk of @entity204 , could be related to imbalances in prognostic variables or other bias in studies. Further research in this area is therefore justified.

Amphetamines for improving recovery after XXXX .

@entity1 :: ('9606', 'Species') :: ['humans', 'patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'Stroke'] @entity889 :: ('MESH:D000662', 'Chemical') :: ['amphetamines'] @entity4944 :: ('MESH:D000661', 'Chemical') :: ['amphetamine'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths'] @entity1779 :: ('MESH:D002543', 'Disease') :: ['cerebral ischaemia']
@entity64 :: (MESH:D020521,Disease) :: ['stroke']
